http://www.forbes.com/sites/matthewherper/2012/12/11/23andme-nabs-billionaire-yuri-milner-as-investor-cuts-price-to-99/
The reinvestment may be a sign, along with sale of DeCode Genetics to Amgen yesterday, in further renewed interest in the power of genetic technologies for the development of drugs and other medical interventions.
No comments:
Post a Comment